Dr. Azra Raza

• 
  www.votec.org/NewsArticles/NVDrRaza08.htm - [Cached Version]
  Published on: 10/7/2008    Last Visited: 6/23/2008  

  In late 2007, Mr. Paravella's New Visions class attended a lecture by internationally recognized cancer expert Dr. Azra Raza.
  ...
  New Visions: Health Careers student Maya Christie (Shenendehowa) wrote the following article about Dr. Raza's visit:
  ...
  Her name was Dr. Azra Raza, a woman who, through her decades of research, has brought us one step closer to discovering a cure for cancer.Born in Pakistan, Dr. Raza excelled in her academics, winning a merit scholarship for five years of medical school, in addition to receiving honors in physics, chemistry, and biology.
  
  In America, Dr. Raza has worked in medical settings such as the University of Maryland Hospital, the Georgetown VA Medical Center and the Department of Hematologic Oncology.Dr. Raza is currently serving as a professor of medicine and the director of the MDS Center at St. Vincent's Comprehensive Cancer Center.Dr. Raza also serves on numerous national and international panels as a reviewer, consultant and advisor.She has authored 226 full-length papers, 15 book chapters, 502 abstracts and has edited a book devoted to MDs.
  
  Furthermore, she has served as the director of a dynamic basic research laboratory and sees approximately 300-400 new MD patients annually.Dr. Raza has spoken at several national, as well as international, conferences as the highly coveted keynote speaker.During her Grand Rounds presentation, she captivated the audience with a brief summary of her cancer research and stressed the importance of healing the "whole" patient, not just the physical aspect.She is currently researching and experimenting with ways in which to reverse the harmful side effects of chemotherapy radiation."Amazing.""Phenomenal.""By far one of the best speakers Ellis has ever had."These were just a few of the positive comments from Dr. Raza's lecture, and we, as New Visions students, were given the once in a lifetime time opportunity to experience this life changing event.

• 
  www.svccc.org/news/index.php - [Cached Version]
  Published on: 3/27/2008    Last Visited: 7/19/2008  

  Azra Raza, MD
  ...
  "A derivative of the drug thalidomide, Revlimid, is FDA-approved for the treatment of transfusion-dependent anemia in patients with lower risk MDS who carry a specific chromosomal abnormality," says Azra Raza, M.D., attending physician and head of the MDS program, St. Vincent's Comprehensive Cancer Center, senior and corresponding author of the study.
  ...
  "The use of genetic testing in MDS to determine how individuals will respond to specific drug therapies not only keeps patients from getting a drug like Revlimid that won't benefit them, but also means they won't be exposed to its potentially toxic side effects," says Dr. Raza.
  ...
  Backed by an outstanding basic research laboratory, the program is headed by Azra Raza, M.D., regarded as one of the world's leading hematologists and experts on MDS.A hallmark of the program is a repository containing approximately 50,000 tissue samples of MDS and acute myeloid leukemia (AML) patients collected by Dr. Raza.A number of exciting, cutting edge clinical trials are open for all stages of MDS and AML patients, including those with early stage disease who are being offered treatment with herbs and other natural substances.Dr. Raza serves on numerous national and international panels as a reviewer, consultant and advisor.
  ...
  St. Vincent's Comprehensive Cancer Center (SVCCC), a center of excellence in hematology oncology, adds Azra Raza, MD, as attending physician in Medical Oncology.Dr. Raza is an internationally recognized specialist in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).The addition of Dr. Raza to its staff is part of an initiative to build SVCCC as a cancer center with subspecialty oncology programs.
  
  Dr. Raza will direct the study and treatment of MDS, which refers to a group of conditions caused by abnormal blood-forming cells of the bone marrow.Considered a relatively rare cancer, 15,000-20,000 new cases are diagnosed annually in the United States.In about 3 out of 10 cases, the MDS will become AML.
  
  Dr. Raza treats 500 to 600 AML and MDS patients from around the United States who travel to receive cutting edge individualized therapies based on molecular and genetic studies of their bone marrows.The MDS program at SVCCC will be unique, in that Dr. Raza has built a national referral base for MDS treatment and research with a large enough population for patients to participate in meaningful clinical trials.
  
  Most recently Dr. Raza was chief, Hematology Oncology and professor of medicine at the University of Massachusetts, and UMass Memorial Medical Center, Worchester, MA. Prior to that appointment, she established the most clinically active and well-funded basic research programs in the United States at Rush Cancer Institute, Chicago, IL, for studying MDS and the leukemias arising from them.
  
  See other Cancer Center News

• 
  www.aptiumoncology.com/about/svccc_raza_032708.html - [Cached Version]
  Published on: 3/27/2008    Last Visited: 8/30/2008  

  "A derivative of the drug thalidomide, Revlimid, is FDA-approved for the treatment of transfusion-dependent anemia in patients with lower risk MDS who carry a specific chromosomal abnormality," says Azra Raza, M.D., attending physician and head of the MDS program, St. Vincent's Comprehensive Cancer Center, senior and corresponding author of the study.
  ...
  "The use of genetic testing in MDS to determine how individuals will respond to specific drug therapies not only keeps patients from getting a drug like Revlimid that won't benefit them, but also means they won't be exposed to its potentially toxic side effects," says Dr. Raza.
  ...
  Backed by an outstanding basic research laboratory, the program is headed by Azra Raza, M.D., regarded as one of the world's leading hematologists and experts on MDS.A hallmark of the program is a repository containing approximately 50,000 tissue samples of MDS and acute myeloid leukemia (AML) patients collected by Dr. Raza.
  
  A number of exciting, cutting edge clinical trials are open for all stages of MDS and AML patients, including those with early stage disease who are being offered treatment with herbs and other natural substances.Dr. Raza serves on numerous national and international panels as a reviewer, consultant and advisor.

• 
  www.biospace.com/news_story.aspx?NewsEntityId=80002 - [Cached Version]
  Published on: 12/8/2007    Last Visited: 12/10/2007  

  "A tremendous need exists for new agents that are well-tolerated and efficacious for the treatment of MDS patients," said Azra Raza, M.D., Professor of Medicine and Director - MDS Program at St. Vincent's Comprehensive Cancer Center in New York City, and lead investigator on the TELINTRA Tablets study.

• 
  www.prnewswire.com/cgi-bin/stories.pl?ACCT=109&STORY=/w - [Cached Version]
  Published on: 12/8/2007    Last Visited: 12/8/2007  

  efficacious for the treatment of MDS patients," said Azra Raza, M.D., Professor of Medicine and Director - MDS Program at St. Vincent's

• 
  www.telegram.com/article/20070702/NEWS/707020319/1092 - [Cached Version]
  Published on: 7/2/2007    Last Visited: 7/3/2007  

  Dr. Rosmarin will take over the hematology/oncology helm from Dr. Azra Raza, who is moving to New York to join the St. Vincent Comprehensive Cancer Center.

• 
  www.svccc.org/news/index.php?p=66 - [Cached Version]
  Published on: 3/27/2008    Last Visited: 7/19/2008  

  Azra Raza, MD
  ...
  "A derivative of the drug thalidomide, Revlimid, is FDA-approved for the treatment of transfusion-dependent anemia in patients with lower risk MDS who carry a specific chromosomal abnormality," says Azra Raza, M.D., attending physician and head of the MDS program, St. Vincent's Comprehensive Cancer Center, senior and corresponding author of the study.
  ...
  "The use of genetic testing in MDS to determine how individuals will respond to specific drug therapies not only keeps patients from getting a drug like Revlimid that won't benefit them, but also means they won't be exposed to its potentially toxic side effects," says Dr. Raza.
  ...
  Backed by an outstanding basic research laboratory, the program is headed by Azra Raza, M.D., regarded as one of the world's leading hematologists and experts on MDS.A hallmark of the program is a repository containing approximately 50,000 tissue samples of MDS and acute myeloid leukemia (AML) patients collected by Dr. Raza.A number of exciting, cutting edge clinical trials are open for all stages of MDS and AML patients, including those with early stage disease who are being offered treatment with herbs and other natural substances.Dr. Raza serves on numerous national and international panels as a reviewer, consultant and advisor.

• 
  www.svccc.com/news/index.php?p=63 - [Cached Version]
  Published on: 10/16/2007    Last Visited: 6/14/2008  

  Azra Raza, MD
  ...
  St. Vincent's Comprehensive Cancer Center (SVCCC), a center of excellence in hematology oncology, adds Azra Raza, MD, as attending physician in Medical Oncology.Dr. Raza is an internationally recognized specialist in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).The addition of Dr. Raza to its staff is part of an initiative to build SVCCC as a cancer center with subspecialty oncology programs.
  
  Dr. Raza will direct the study and treatment of MDS, which refers to a group of conditions caused by abnormal blood-forming cells of the bone marrow.Considered a relatively rare cancer, 15,000-20,000 new cases are diagnosed annually in the United States.In about 3 out of 10 cases, the MDS will become AML.
  
  Dr. Raza treats 500 to 600 AML and MDS patients from around the United States who travel to receive cutting edge individualized therapies based on molecular and genetic studies of their bone marrows.The MDS program at SVCCC will be unique, in that Dr. Raza has built a national referral base for MDS treatment and research with a large enough population for patients to participate in meaningful clinical trials.
  
  Most recently Dr. Raza was chief, Hematology Oncology and professor of medicine at the University of Massachusetts, and UMass Memorial Medical Center, Worchester, MA. Prior to that appointment, she established the most clinically active and well-funded basic research programs in the United States at Rush Cancer Institute, Chicago, IL, for studying MDS and the leukemias arising from them.

• 
  icore.ca/summit/summit07/summit07_program_topics.htm - [Cached Version]
  Published on: 9/1/2006    Last Visited: 9/25/2007  

  Azra Raza
  ...
  KEYNOTE: Dr Azra RazaClinical Hematology, University of Massachusetts
  ...
  Dr Raza is the Gladys Smith Martin Professor of Oncology, Professor of Medicine, Chief of Hematology and Associate Clinical Director of the Cancer Center at the University of Massachusetts (UMass), Worcester, MA.Dr Raza completed her medical education in Pakistan, training in Internal Medicine at the University of Maryland, Franklin Square Hospital and Georgetown/VA Medical Center in Washington, D.C. and her fellowship in Medical Oncology at Roswell Park Cancer Institute in Buffalo, New York.She started her research in Myelodysplastic Syndromes (MDS) in 1982, moved briefly to Cincinnati, Ohio and then to Chicago, Illinois in 1992, where she established a highly productive translational research program in MDS.This program, along with a Tissue Repository containing more than 40,000 samples from MDS patients was successfully relocated to UMass in 2004.Dr Raza has authored 230 full-length papers, 15 book chapters, 510 abstracts, and edited a book devoted to MDS.She has been the Director of a dynamic basic research laboratory, and sees approximately 4-500 new MDS patients a year at the Radhey Khanna MDS Center at UMass.There are 20+ clinical trials open for all stages of MDS patients at this center, including those with early stage MDS who are being offered treatment with natural substances.Over 200 MDS/AML patients are accrued on these Phase I-III clinical trials annually.Dr Raza serves on numerous National and International panels as a reviewer, consultant and advisor.

• 
  www.genomicsproteomics.com/index.aspx?ID=90989 - [Cached Version]
  Published on: 3/27/2008    Last Visited: 8/2/2008  

  "A derivative of the drug thalidomide, Revlimid is FDA-approved for the treatment of transfusion-dependent anemia in patients with lower risk MDS who carry a specific chromosomal abnormality," says Azra Raza, M.D., attending physician and head of the MDS program, St. Vincent's Comprehensive Cancer Center, senior and corresponding author of the study.
  ...
  "The use of genetic testing in MDS to determine how individuals will respond to specific drug therapies not only keeps patients from getting a drug like Revlimid that won't benefit them, but also means they won't be exposed to its potentially toxic side effects," says Dr. Raza.

Page:  1 2 3 4